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Summary Twenty-two asymptomatic women with rising CA 125 levels after chemotherapy for ovarian cancer
were entered into a trial of isotretinoin combined with calcitriol. Tumours were evaluated according to precise
criteria based on serial CA 125 levels and by comparing regression slopes of CA 125 before and during
therapy. There was no evidence based on CA 125 of any responses or significant change in tumour growth rate.
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Retinoids have been shown in vitro and in animal
experiments to have inhibitory activity against a wide range
of solid tumours. The single-agent activity in man has been
disappointing apart from in acute promyelocytic leukaemia
(Smith et al., 1992). However, combination therapy with
interferon has shown considerable activity against cervical
carcinoma (Lippman et al., 1992). This has suggested that
retinoids should be tested with a variety of other biologically
active agents. The vitamin D metabolite, 1,25 dihydroxy
vitamin D3 (calcitriol), is one agent that has shown additive
or synergistic activity on differentiation, angiogenesis and
proliferation when combined with retinoids (Bollag et al.,
1994). A trial of alphacalcidol in low-grade non-Hodgkin's
lymphoma showed evidence of response in four of seven
patients (Rains et al., 1991). Topical calcipotriol produced
partial responses in three of 14 patients with drug-resistant
breast carcinoma (Bower et al., 1991). The combination of
isotretinoin (13 cis-retinoic acid) and calcitriol has been
shown to lead to remissions in some patients with cutaneous
T-cell lymphoma, basal cell and squamous cell carcinomas
(French et al., 1994; Majewski et al., 1994; Thomsen, 1995).
Ovarian cancer was chosen for the investigation of
retinoids as all-trans retinoic acid causes growth inhibition
in ovarian carcinoma cell lines (Caliaro et al., 1994).
Additional factors favouring ovarian carcinoma are that it
is rarely associated with hypercalcaemia, and relapsing
tumour detected by rising levels of serum CA 125 can be
asymptomatic for several months (Van der Burg et al., 1990).
These patients can, therefore, receive the isotretinoin and
calcitriol combination for a sufficient period, so that
stabilisation of disease owing to tumour differentiation can
be manifested. CA 125 is elevated in over 90% of patients
with advanced ovarian cancer and has been shown to predict
tumour response and progression accurately (Rustin et al.,
1993, 1996a, b), but this is, to our knowledge, the first trial in
which it has been used as the main mediator of efficacy.
Patients and methods
All eligible patients had histologically or cytologically proven
diagnosis of epithelial ovarian carcinoma. Essential criteria
were: prior treatment with at least one standard chemother-
apy regimen, a greater than 3 month interval since
completing the last course of chemotherapy; progression of
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disease, defined as a CA 125 level that had risen to more than
100 U ml-'; a Karnofsky performance status of at least 60;
an ability to take oral medication; a serum creatinine less
than 1.5 x upper limit of normal; LFTs and bilirubin less
than 2 x upper limit of normal; serum calcium within normal
range; and no serious concomitant physical or psychiatric
disease.
Treatment consisted of isotretinoin 1 mg kg-' per day
orally, which was continued throughout the study, unless
they experienced severe cheilitis or skin toxicity, when the
dose was halved. Calcitriol was taken orally initially at a dose
of 0.5 Mg per day. It was escalated every week by 0.5 ,g, to a
maximum of 4 ,g, provided the corrected serum calcium
remained below 3 mmol-'1. Calcitriol was taken at least 4 h
after the last meal to reduce absorption of calcium from the
gut, and thus reduce the risk of hypercalcaemia. Calcitriol
was stopped for 1 week if the serum calcium rose above
3 mmol '1, and then reintroduced at 1 Mg a day less than
previously. Other treatments were allowed to be administered
as required, provided the treatment was not known to affect
the tumour type in question.
Toxicity was recorded daily by patients using a diary card.
This listed the expected toxicities and asked patients to assign
a number against each toxicity each day, recording 0 as no
toxicity, 1 as a little, 2 as moderate and 3 as severe. Patients
were considered evaluable for toxicity if they completed 1
month of treatment. They continued treatment, toxicity
permitting, until there was evidence of disease progression.
This progression could be clinical, radiological or defined
according to serum CA 125, if after two samples there was a
25% rise confirmed by a fourth sample, or a serial rise of
50% over three samples (Rustin et al., 1993).
Serum calcium was measured weekly for the first 8 weeks
and then monthly thereafter. Serum CA 125 was assessed
with similar frequency. Full blood count, renal and liver
function were assessed monthly.
Statistical analysis
The regression slope of serial CA 125 levels in log units was
calculated before and during therapy. For each patient, serial
CA 125 levels during the trial period were compared with
levels over the equivalent time period immediately before the
treatment. If the patient had undergone other anti-cancer
therapy within that preceding period, then the pretrial
CA 125 trend was taken from the end of that therapy.
Response according to CA 125 was also predicted to have
occurred if, after two samples, there had been a 50% fall,
confirmed by a fourth sample, or there had been a serial fall
of 75% over three samples. The final sample had to be at
least 28 days after the previous sample (Rustin et al., 1996a).Ao.,& isotretinoin and caicitriol trial in ovarian cancer
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In order not to miss minor falls in CA 125 levels, the above
definitions were also modified to examine 40% and 10% falls
in CA 125 levels.
Results
A total of 22 patients were treated in this study, 14 at Mount
Vernon Hospital and eight at the Charing Cross Hospital.
The duration of therapy is shown in Table I. Breaks in
therapy occurred as a result of corrected serum calcium
> 3.0 mmol ' 1 in 11 patients, holiday in one patient, surgery
in another and both hypercalcaemia and unexplained hip
pains in another. The maximum achievable dose of calcitriol
was 4.0 ,ug in three patients, 3.5 ig in one, 3.0 ,ug in five,
2.5 Mg in four, 2.0 Mg in six, 1.5 Mg in two and 1.0 Mg in one.
The corrected serum calcium was >3 mmol-1 1 in 14
patients, but this level was not reached in the three patients
who achieved 4.0 Mug calcitriol. The reasons for going off
study were clinical tumour progression in 15 cases, patient
request because of restriction on eating before taking
calcitriol in two cases (one after 44 weeks on study), and
toxicity plus knowledge of rising CA 125 in two more. Two
patients came of study after 65 and 85 weeks before surgery.
Toxicity
The trial therapy was generally well tolerated, possibly
because these patients had all received prior cisplatin or
carboplatin, which was far more toxic. Patients were all
advised on use of moisturising creams and lip balms to
reduce the toxicity. Table II summarises the most severe side-
effects experienced by 22 patients during the study. Toxicity
data were not recorded in the patient who came off study
after just 2 weeks. The highest grade of toxicity according to
NCIC/CTC criteria wvas: haemoglobin grade 2, three patients;
grade 1, five patients; lymphocytes grade 2, one patient; grade
1, six patients; no white blood cell or platelet toxicity;
creatinine grade 3, one patient; grade 2, one patient; grade 1,
ten patients; alkaline phosphatase grade 2, one patient; grade
1, five patients.
Table I Duration on time study
Weeks on studya Number ofpatients Number with breaks
<4 1 0
4-8 5 1
9-20 9 5
21-74+ 7 7
'Actual weeks receiving both isotretinoin and calcitriol, excluding
breaks owing to hypercalcaemia.
Table II Toxicity
Toxicity Grade I Grade 2 Grade 3
Sore lips 7 11 4
Dry skin 7 10 2
Sore eyes 8 4 2
Nausea 3 4 7
Vomiting 5 4 1
Joint aches 6 3 8
Skin rash 6 2 3
Fatigue 5 5 3
Headaches 6 4 0
Anorexia 4 6 1
Pain 5 6 3
Hair loss 4 2 0
Mouth ulcers 3 0 0
Constipation 0 2 1
Dizziness 1 0 0
Maximum toxicity based on diary cards completed by 22 patients.
Grade l, a little; 2, moderate; 3, severe.
Tumour response
Sixteen patients received at least 9 weeks of isotretinoin and
calcitriol and were considered evaluable for response
according to CA 125 criteria. No patients had a 50% or
75% response according to our CA 125 definitions (Rustin et
al., 1996a). When the percentage fall of CA 125 levels was
reduced to 40% to qualify for a response, one patient was
classified as 'improving', and when reduced to a 10% fall,
two patients were classified as 'improving'. The regression
slope of CA 125 in log units increased in six cases during
therapy, and in ten cases it decreased compared with the
pretreatment regression slope. This provides no evidence of a
treatment effect (P=0.45) (binomial test). Clinical evidence of
tumour progression while on therapy was seen in 11 of 17
evaluable patients. A serial rise in CA 125 levels of >25%
was seen in 12 of 16 evaluable patients during the study.
Three of the 16 evaluable patients have no evidence of
tumour progression on study. One of these stopped after 44
weeks at her request and had a treatment-free interval before
entering the study of almost 4 years, suggesting a slowly
progressive tumour. Another with a treatment-free interval of
almost 2 years continues on therapy after 52 weeks, as her
CA 125 level has plateaued. The only patient who may have
benefited from this trial had a stage 3 borderline serous
carcinoma diagnosed in 1984. Since 1990, she has received
five different chemotherapy regimens for symptomatic
progressive tumour before starting on the isotretinoin and
calcitriol trial. There has been a steady decline in CA 125
levels since then, and she has remained symptomatically
better than at any period since 1990. Apart from a few delays
caused by hypercalcaemia and unexplained hip pain that
resolved spontaneously, she continued on study in for 85
weeks. Remaining tumour was then removed surgically.
Disscussion
The absence of any responses among 16 evaluable patients
suggests that treatment of recurrent ovarian carcinoma with a
combination of isotretin and calcitriol is not effective. There
was probable benefit in one patient with borderline ovarian
serous carcinoma, which was behaving in a malignant,
invasive manner. That this woman has had a longer period
without progression since on this combination than after any
of her previous five lines of chemotherapy is suggestive of
some effect on her tumour.
The previous reports of responses to isotretinoin and
calcitriol were all in tumour types that have been associated
with responses to retinoids alone. The lack of responses to
this combination in patients with ovarian carcinoma could
be a result of this tumour type lacking the appropriate
receptors. Animal studies have shown responses of breast
cancer to combinations of retinoids and hormones or
cytokines. It would be difficult to test this combination in
patients with breast cancer owing to the associated high
incidence of hypercalcaemia. New vitamin D analogues,
which have a greater anti-proliferative than hypercalcaemic
effect, will enable these studies to take place (Coombes,
1993).
This study has demonstrated the merits of using serum
CA 125 for new drug evaluation. Patients who have a
confirmed rise of CA 125 levels that have risen to twice the
upper limit of normal after initial chemotherapy for ovarian
carcinoma were shown in a study of 130 evaluable women to
have a greater than 98% chance of developing clinical
evidence of tumour progression (Rustin et al., 1996b).
Requiring a rise of CA 125 to > 100 U ml-' is even stronger
evidence of recurrent disease. It is currently unclear whether
early reintroduction of chemotherapy is of any value to these
women, many of whom will remain free of symptoms for
long periods. Once these women are aware of a rising CA 125
value, many desire some form oftherapy. They are, therefore,
ideal candidates for assessment of drugs, such as differentiat-Isotretinoin and calcitriol trial in ovarian cancer
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ing or anti-metastatic agents, that may only induce disease
stabilisation and may require to be given for long periods to
asymptomatic women.
Many studies have included analysis of CA 125 trends
during therapy, but we believe that this is the first study in
which CA 125 was the main method of tumour assessment.
We have previously shown that response to initial
chemotherapy can be accurately measured by using precise
definitions based on either a 50% or 75% fall in CA 125
levels (Rustin et al., 1996a). These response definitions based
on CA 125 have been studied in phase II trials of seven
different new drugs and in each case have clearly shown
which drugs are active and which are inactive (Rustin et al.,
1996c). The lack of responses according to CA 125 in the
present study can. therefore, be relied upon. Because we were
also looking for disease stabilisation, we examined the rate of
rise of CA 125 during therapy and compared this slope with
a similar period before therapy. The lack of significant
difference between the regression slopes plus the observation
of clinical progression in 11 of 16 evaluable patients is
evidence that the vitamin combination did not induce
stabilisation. The observation that a >25% rise in CA 125
levels was seen in 12 of 16 evaluable women during the
therapy is further evidence of tumour progression.
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